PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...

Recent research shows the incredible success of radiofrequency ablation in treating AFib, offering renewed hope for patients.

AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...

The following variables were extracted from each study: number of patients, sex, mean age, predictors of AF and thromboembolism ... but most included patients with paroxysmal and chronic AF. Six ...

Analysts at Jefferies have previously said that iptacopan could hit $3.6 billion in peak annual sales if it gets approved for all its target indications, which along with PNH and IgAN include ...

On the instructions of Rameau Normil, Acting Director General of the National Police of Haiti (PNH), Divisional Commissioner Jean Gabriel Gabart, Acting Departmental Director of the South-East Police, ...

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The European ...

by Dr Thara Balasubramaniam, Dr Richard Kelly, Dr Anita Hill and Professor Peter Hillmen ...

Equities research analysts at Wedbush boosted their FY2024 EPS estimates for Apellis Pharmaceuticals in a research report ...